07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Domain Therapeutics, Mavalon Therapeutics deal

Domain formed single-asset, U.K.-based newco Mavalon Therapeutics with an investment of up to EUR9 million ($9.9 million) from Medicxi Ventures . Domain also granted Mavalon rights to positive allosteric modulators of metabotropic glutamate receptor subtype...